Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $110
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $88 to $110.
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $88 to $110.